Warfarin pharmacokinetics and pharmacodynamics are not affected by concomitant administration of the long-acting GLP-1 receptor agonist polyethylene glycol loxenatide

To evaluate potential drug-drug interactions between polyethylene glycol loxenatide (PEX-168) and warfarin.